Gavin Henry, a thoracic surgeon and chair of thoracic surgery at the University of Maryland Baltimore Washington Medical Center (UM BWMC), has been appointed the new medical director of the Tate Cancer Center.
Henry’s appointment comes as the Tate Cancer Center celebrates its 20th year of providing multidisciplinary cancer care to more than 20,000 patients.
Henry joined the University of Maryland Medical System (UMMS), parent organization of UM BWMC, in 2017 as the director of clinical operations for the division of thoracic surgery. He is also an assistant professor of surgery at the University of Maryland School of Medicine. Henry specializes in treating conditions of the esophagus and lung and performing minimally invasive robotic surgeries for most thoracic procedures. He also leads the lung cancer screening program at the Tate Cancer Center at UM BWMC.
In his new role, Henry will aim to grow the academic and clinical missions of the Tate Cancer Center through its affiliation with the University of Maryland Cancer Network and make the benefits of discovery-based medicine more accessible to people in Anne Arundel County and the surrounding communities.
“Dr. Henry brings a wealth of experience and knowledge to the Tate Cancer Center,” said Kathy McCollum, president and chief executive officer of UM BWMC. “With his expertise, we’ll continue to cement the reputation of the Tate Cancer Center and UM BWMC as a leader in cancer care and create greater access to clinical research across the state and in our communities.”
Named for community philanthropists Creston and Betty Tate, the Tate Cancer Center provides a full spectrum of cancer care services that combines clinical expertise and innovative treatments with supportive services to create the best treatment plans for each individual patient.
“Over the last 20 years, the Tate Cancer Center at UM BWMC has achieved significant milestones in cancer care and better supported individuals throughout all stages of their journey thanks to the incredible support we’ve received from the community and the expertise of our team members,” McCollum said.
Key to the Tate Cancer Center’s success has been its multidisciplinary approach to treating cancer – bringing together surgeons, medical and radiation oncologists, diagnostic radiology, pathology and other cancer specialists to develop individualized treatment plans for each patient. The center also connects patients to support services, including genetic counseling, nutritional services, financial counseling and palliative care.
The center also offers clinical trials designed to find new and better ways to treat patients with cancer, and it trains the next generation of cancer care providers. Last year, the Tate Cancer Center received its reaccreditation from the Commission on Cancer as an Academic Comprehensive Cancer Program. To earn the designation, the Tate Cancer Center provides post-graduate medical education, diagnoses or treats at least 500 new cancer cases each year, offers a full range of diagnostic and treatment services, and participates in cancer-related clinical research. Only 13% of all cancer programs in the nation have achieved this status.
“The future is in clinical research,” Henry said. “In order for us to get ahead and defeat cancer, clinical research is going to be increasingly important. I’m confident that together with the clinical and non-clinical teams at the Tate Cancer Center and UM Cancer Network, the next two decades are going to be even better, with more innovations and breakthroughs to come.”
No comments on this item Please log in to comment by clicking here